SIRT3 activator Honokiol attenuates β-Amyloid by modulating amyloidogenic pathway

Honokiol (poly-phenolic lignan from Magnolia grandiflora) is a Sirtuin-3 (SIRT3) activator which exhibit antioxidant activity and augment mitochondrial functions in several experimental models. Modern evidence suggests the critical role of SIRT3 in the progression of several metabolic and neurodegenerative diseases. Amyloid beta (Aβ), the precursor to extracellular senile plaques, accumulates in the brains of patients with Alzheimer’s disease (AD) and is related to the development of cognitive impairment and neuronal cell death. Aβ is generated from amyloid-β precursor protein (APP) through sequential cleavages, first by β-secretase and then by γ-secretase. Drugs modulating this pathway are believed to be one of the most promising strategies for AD treatment. In the present study, we found that Honokiol significantly enhanced SIRT3 expression, reduced reactive oxygen species generation and lipid peroxidation, enhanced antioxidant activities, and mitochondrial function thereby reducing Aβ and sAPPβ levels in Chinese Hamster Ovarian (CHO) cells (carrying the amyloid precursor protein-APP and Presenilin PS1 mutation). Mechanistic studies revealed that Honokiol affects neither protein levels of APP nor α-secretase activity. In contrast, Honokiol increased the expression of AMPK, CREB, and PGC-1α, thereby inhibiting β-secretase activity leading to reduced Aβ levels. These results suggest that Honokiol is an activator of SIRT3 capable of improving antioxidant activity, mitochondrial energy regulation, while decreasing Aβ, thereby indicating it to be a lead compound for AD drug development.

[1]  M. Buabeid,et al.  Immunological alteration & toxic molecular inductions leading to cognitive impairment & neurotoxicity in transgenic mouse model of Alzheimer's disease , 2017, Life sciences.

[2]  Nazanin Mirzaei,et al.  PPARγ-coactivator-1α gene transfer reduces neuronal loss and amyloid-β generation by reducing β-secretase in an Alzheimer’s disease model , 2016, Proceedings of the National Academy of Sciences.

[3]  Zhi-xiu Lin,et al.  Neuroprotective effects of honokiol against beta-amyloid-induced neurotoxicity via GSK-3β and β-catenin signaling pathway in PC12 cells , 2016, Neurochemistry International.

[4]  T. Lai,et al.  Amyloid-β suppresses AMP-activated protein kinase (AMPK) signaling and contributes to α-synuclein-induced cytotoxicity , 2016, Experimental Neurology.

[5]  Y. Chen,et al.  Glucose regulates amyloid β production via AMPK , 2015, Journal of Neural Transmission.

[6]  D. Holtzman,et al.  Three dimensions of the amyloid hypothesis: time, space and 'wingmen' , 2015, Nature Neuroscience.

[7]  S. Tangvarasittichai.  Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. , 2015, World journal of diabetes.

[8]  Anil Kumar,et al.  A review on Alzheimer’s disease pathophysiology and its management: an update , 2015, Pharmacological reports : PR.

[9]  Dean P. Jones,et al.  Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial SIRT3 , 2015, Nature Communications.

[10]  Y. Fukuyama,et al.  Nonpeptide neurotrophic agents useful in the treatment of neurodegenerative diseases such as Alzheimer's disease. , 2015, Journal of pharmacological sciences.

[11]  C. Arias,et al.  Cellular and metabolic alterations in the hippocampus caused by insulin signalling dysfunction and its association with cognitive impairment during aging and Alzheimer's disease: studies in animal models , 2015, Diabetes/metabolism research and reviews.

[12]  N. Turner,et al.  Mitochondrial dysfunction and insulin resistance: an update , 2014, Endocrine connections.

[13]  T. Denney,et al.  The role of frataxin in doxorubicin‐mediated cardiac hypertrophy (648.6) , 2014, American journal of physiology. Heart and circulatory physiology.

[14]  J. Silberring,et al.  Metabolism of Cryptic Peptides Derived from Neuropeptide FF Precursors: The Involvement of Insulin-Degrading Enzyme , 2014, International journal of molecular sciences.

[15]  P. Picone,et al.  Mitochondrial Dysfunction: Different Routes to Alzheimer's Disease Therapy , 2014, Oxidative medicine and cellular longevity.

[16]  R. Swerdlow,et al.  The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. , 2014, Biochimica et biophysica acta.

[17]  S. M. de la Monte,et al.  Brain metabolic dysfunction at the core of Alzheimer's disease. , 2014, Biochemical pharmacology.

[18]  Hoau Yan Wang,et al.  The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease , 2014, Alzheimer's & Dementia.

[19]  S. Noha,et al.  Honokiol: A non-adipogenic PPARγ agonist from nature☆ , 2013, Biochimica et biophysica acta.

[20]  Zhichun Chen,et al.  Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: Implications for diagnostic and therapeutic strategies , 2013, Progress in Neurobiology.

[21]  Ling Wei,et al.  Neuro-Modulating Effects of Honokiol: A Review , 2013, Front. Neurol..

[22]  Dan-shen Zhang,et al.  Oxidative stress, mitochondrial damage and neurodegenerative diseases , 2013, Neural regeneration research.

[23]  Julie St-Pierre,et al.  PGC1&agr; and mitochondrial metabolism – emerging concepts and relevance in ageing and neurodegenerative disorders , 2012, Journal of Cell Science.

[24]  C. Sutherland,et al.  Insulin resistance in the brain: an old-age or new-age problem? , 2012, Biochemical pharmacology.

[25]  M. Mattson,et al.  Soluble amyloid precursor protein-α modulates β-secretase activity and amyloid-β generation , 2012, Nature Communications.

[26]  S. Weggen,et al.  Autoreactive‐Aβ antibodies promote APP β‐secretase processing , 2012, Journal of neurochemistry.

[27]  S. Monte.  Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimer's Disease , 2012 .

[28]  S. Monte.  Contributions of Brain Insulin Resistance and Deficiency in Amyloid-Related Neurodegeneration in Alzheimer’s Disease , 2012, Drugs.

[29]  H. Soininen,et al.  Midlife vascular risk factors and Alzheimer's disease: evidence from epidemiological studies. , 2012, Journal of Alzheimer's disease : JAD.

[30]  M. Chaves,et al.  Mechanisms of Brain Aging Regulation by Insulin: Implications for Neurodegeneration in Late-Onset Alzheimer's Disease , 2011, ISRN neurology.

[31]  Hui Zheng,et al.  Biology and pathophysiology of the amyloid precursor protein , 2011, Molecular Neurodegeneration.

[32]  S. H. Kim,et al.  Neuronal Sirt3 Protects against Excitotoxic Injury in Mouse Cortical Neuron Culture , 2011, PloS one.

[33]  S. Weggen,et al.  Presenilin‐1 but not amyloid precursor protein mutations present in mouse models of Alzheimer’s disease attenuate the response of cultured cells to γ‐secretase modulators regardless of their potency and structure , 2011, Journal of neurochemistry.

[34]  Y. Yun,et al.  4-O-methylhonokiol attenuated memory impairment through modulation of oxidative damage of enzymes involving amyloid-β generation and accumulation in a mouse model of Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[35]  N. Bogdanovic,et al.  PPARγ co-activator-1α (PGC-1α) reduces amyloid-β generation through a PPARγ-dependent mechanism. , 2011, Journal of Alzheimer's disease : JAD.

[36]  Huaxi Xu,et al.  APP processing in Alzheimer's disease , 2011, Molecular Brain.

[37]  Danica Chen,et al.  Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. , 2010, Cell metabolism.

[38]  A. Hofman,et al.  Insulin metabolism and the risk of Alzheimer disease , 2010, Neurology.

[39]  Wei Yu,et al.  Sirt3 Mediates Reduction of Oxidative Damage and Prevention of Age-Related Hearing Loss under Caloric Restriction , 2010, Cell.

[40]  S. Jo,et al.  Swedish mutation within amyloid precursor protein modulates global gene expression towards the pathogenesis of Alzheimer's disease. , 2010, BMB reports.

[41]  A. Chow,et al.  Neuroprotective effect of honokiol and magnolol, compounds from Magnolia officinalis, on beta‐amyloid‐induced toxicity in PC12 cells , 2010, Phytotherapy research : PTR.

[42]  Huabing Zhang,et al.  Sirtuin 3, a New Target of PGC-1α, Plays an Important Role in the Suppression of ROS and Mitochondrial Biogenesis , 2010, PloS one.

[43]  J. Orgogozo,et al.  Improved Mitochondrial Function in Brain Aging and Alzheimer Disease – the New Mechanism of Action of the Old Metabolic Enhancer Piracetam , 2010, Front. Neurosci..

[44]  J. Simon,et al.  AMP-activated Protein Kinase Signaling Activation by Resveratrol Modulates Amyloid-β Peptide Metabolism* , 2010, The Journal of Biological Chemistry.

[45]  George Perry,et al.  Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. , 2010, Biochimica et biophysica acta.

[46]  Robert V Farese,et al.  SIRT 3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation , 2010 .

[47]  M. Jendrach,et al.  Mitochondrial dysfunction: An early event in Alzheimer pathology accumulates with age in AD transgenic mice , 2009, Neurobiology of Aging.

[48]  Q. Tong,et al.  Diet and exercise signals regulate SIRT3 and activate AMPK and PGC-1α in skeletal muscle , 2009, Aging.

[49]  J. Buxbaum,et al.  PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. , 2009, Archives of neurology.

[50]  V. Suppiramaniam,et al.  Neurotoxic Effects of Methamphetamine , 2009, Neurochemical Research.

[51]  Shiwei Song,et al.  A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis , 2008, Proceedings of the National Academy of Sciences.

[52]  S. Heales,et al.  Oxidative stress and mitochondrial dysfunction in neurodegeneration; cardiolipin a critical target? , 2008, Biochimica et biophysica acta.

[53]  H. Fukui,et al.  The mitochondrial impairment, oxidative stress and neurodegeneration connection: reality or just an attractive hypothesis? , 2008, Trends in Neurosciences.

[54]  W. C. Hallows,et al.  Where in the cell is SIRT3?--functional localization of an NAD+-dependent protein deacetylase. , 2008, The Biochemical journal.

[55]  M. Mattson,et al.  Oxidative stress activates a positive feedback between the γ‐ and β‐secretase cleavages of the β‐amyloid precursor protein , 2007 .

[56]  B. Spiegelman,et al.  AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α , 2007, Proceedings of the National Academy of Sciences.

[57]  P. Bickford,et al.  Oxidative Stress and the Aging Brain: From Theory to Prevention , 2007 .

[58]  D. Leibfritz,et al.  Free radicals and antioxidants in normal physiological functions and human disease. , 2007, The international journal of biochemistry & cell biology.

[59]  S. Craft.  Insulin Resistance Syndrome and Alzheimer Disease: Pathophysiologic Mechanisms and Therapeutic Implications , 2006, Alzheimer disease and associated disorders.

[60]  J. Quinn,et al.  Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. , 2006, Human molecular genetics.

[61]  M. Folstein,et al.  Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimer's disease: review and hypothesis , 2006, Neurobiology of Aging.

[62]  P. Reddy,et al.  Can herbs provide a new generation of drugs for treating Alzheimer's disease? , 2005, Brain Research Reviews.

[63]  Izumi Horikawa,et al.  Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. , 2005, Molecular biology of the cell.

[64]  A. Artola,et al.  Insulin modulates hippocampal activity‐dependent synaptic plasticity in a N‐methyl‐d‐aspartate receptor and phosphatidyl‐inositol‐3‐kinase‐dependent manner , 2005, Journal of neurochemistry.

[65]  Q. Tong,et al.  SIRT3, a Mitochondrial Sirtuin Deacetylase, Regulates Mitochondrial Function and Thermogenesis in Brown Adipocytes* , 2005, Journal of Biological Chemistry.

[66]  J. Wands,et al.  Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? , 2005, Journal of Alzheimer's disease : JAD.

[67]  J. Gee,et al.  Autophagy, proteasomes, lipofuscin, and oxidative stress in the aging brain. , 2004, The international journal of biochemistry & cell biology.

[68]  R. Mayeux,et al.  Hyperinsulinemia and risk of Alzheimer disease , 2004, Neurology.

[69]  D. Alkon,et al.  Insulin and the insulin receptor in experimental models of learning and memory. , 2004, European journal of pharmacology.

[70]  H. Cai,et al.  Amyloid β peptide load is correlated with increased β-secretase activity in sporadic Alzheimer's disease patients , 2004 .

[71]  C. Peers,et al.  Hypoxic remodelling of Ca2+ mobilization in type I cortical astrocytes: involvement of ROS and pro‐amyloidogenic APP processing , 2003, Journal of neurochemistry.

[72]  H. Cai,et al.  Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[73]  K. Morgan,et al.  Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease. , 2003, The international journal of biochemistry & cell biology.

[74]  E. Ravussin,et al.  Calorie restriction and aging: review of the literature and implications for studies in humans. , 2003, The American journal of clinical nutrition.

[75]  Matthew P. Frosch,et al.  Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[76]  P. Puigserver,et al.  Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. , 2003, Endocrine reviews.

[77]  B. Spiegelman.  Peroxisome Proliferator-Activated Receptor-Coactivator 1 ( PGC-1 ) : Transcriptional Coactivator and Metabolic Regulator , 2003 .

[78]  P. Wong,et al.  Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease , 2003, Nature Medicine.

[79]  George Perry,et al.  Role of mitochondrial dysfunction in Alzheimer's disease , 2002, Journal of neuroscience research.

[80]  J. Wands,et al.  Chronic gestational exposure to ethanol impairs insulin-stimulated survival and mitochondrial function in cerebellar neurons , 2002, Cellular and Molecular Life Sciences CMLS.

[81]  C. Arias,et al.  β‐Amyloid peptide induces ultrastructural changes in synaptosomes and potentiates mitochondrial dysfunction in the presence of ryanodine , 2002, Journal of neuroscience research.

[82]  A. Nunomura,et al.  Oxidative Damage Is the Earliest Event in Alzheimer Disease , 2001, Journal of neuropathology and experimental neurology.

[83]  S. Hoyer,et al.  Inhibition of the Neuronal Insulin Receptor An in Vivo Model for Sporadic Alzheimer Disease? , 2000, Annals of the New York Academy of Sciences.

[84]  S. Hoyer,et al.  Inhibition of the Neuronal Insulin Receptor Causes Alzheimer‐like Disturbances in Oxidative/Energy Brain Metabolism and in Behavior in Adult Rats , 1999, Annals of the New York Academy of Sciences.

[85]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[86]  L. Hersh,et al.  Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation* , 1998, The Journal of Biological Chemistry.

[87]  K. Mohanakumar,et al.  Neuroprotection by bromocriptine against 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced neurotoxicity in mice1 , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[88]  M. Smith,et al.  Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. , 1998, The American journal of pathology.

[89]  M. Williams,et al.  Development of Insulin Resistance in 3T3-L1 Adipocytes* , 1997, The Journal of Biological Chemistry.

[90]  J. Hardy,et al.  Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.

[91]  A. Schapira,et al.  Oxidative stress and mitochondrial dysfunction in neurodegeneration , 1996, Current opinion in neurology.

[92]  D. Selkoe,et al.  The Swedish mutation causes early-onset Alzheimer's disease by β-secretase cleavage within the secretory pathway , 1995, Nature Medicine.

[93]  R. Ramsay,et al.  Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. , 1986, Biochemical and biophysical research communications.

[94]  R. Burk,et al.  Glutathione peroxidase activity in selenium-deficient rat liver. , 1976, Biochemical and biophysical research communications.

[95]  S. Marklund,et al.  Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. , 1974, European journal of biochemistry.

[96]  A. Tzagoloff,et al.  [45] Cytochrome oxidase from beef heart mitochondria , 1967 .

[97]  E. Wills,et al.  MECHANISMS OF LIPID PEROXIDE FORMATION IN TISSUES. ROLE OF METALS AND HAEMATIN PROTEINS IN THE CATALYSIS OF THE OXIDATION UNSATURATED FATTY ACIDS. , 1965, Biochimica et biophysica acta.

[98]  I W SIZER,et al.  A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. , 1952, The Journal of biological chemistry.